1039

Апластическая анемия - это заболевание, при котором костный мозг не производит достаточного количества клеток крови. Дефицит всех типов клеток крови - белых кровяных телец (лейкоцитов), красных кровяных телец (эритроцитов) и тромбоцитов - может привести к образованию заболевания, называемого панцитопенией. Лечение этого заболевания очень актуально. Об этом и пойдет речь в этой статье. 

  • Название журналаRE-HEALTH
  • Номер выпуска2.3-2020
  • Количество просмотров 1039
  • Количество прочтений 911
  • Дата публикации 30-01-2021
  • Язык статьиRus
  • Страницы23-30
Русский

Апластическая анемия - это заболевание, при котором костный мозг не производит достаточного количества клеток крови. Дефицит всех типов клеток крови - белых кровяных телец (лейкоцитов), красных кровяных телец (эритроцитов) и тромбоцитов - может привести к образованию заболевания, называемого панцитопенией. Лечение этого заболевания очень актуально. Об этом и пойдет речь в этой статье. 

English

Aplastic anemia is a disease in which the bone marrow does not produce enough blood cells. Deficiency of all blood cell types - white blood cells (leukocytes), red blood cells (erythrocytes) and platelets - can lead to the formation of a disease called pancytopenia. For the treatment of aplastic anemia, medications, blood transfusions, or bone marrow transplants (stem cell transplants) are performed. Treatment of this disease is very topical. This will be discussed in this article.

Ўзбек

Aplastik anemiya bu suyak iligi yetarli miqdordagi qon hujayralarini ishlab chiqarmasligi bilan kechadigan kasallik. Barcha qon hujayra turlarining yetishmasligi kelib chiqishi  mumkin - oq qon hujayralari (leykotsitlar), qizil qon hujayralari (eritrotsitlar) va trombotsitlar - bu pansitopeniya deb ataladigan kasallikning shakllanishiga olib keladi. Ushbu kasallikni davolash juda dolzarbdir. Bu esa ushbu maqolada muhokama qilinadi. 

№ Название ссылки
1 1. Aplastic anemia. National Heart, Lung, and Blood Institute. https://www.nhlbi.nih.gov/health-topics/aplastic-anemia. Accessed Nov. 16, 2019.
2 2. Olson TS. Treatment of aplastic anemia in adults. https://www.uptodate.com/contents/search. Accessed Nov. 16, 2019.
3 3. Aplastic anemia. Aplastic Anemia and MDS International Foundation. https://www.aamds.org/diseases/aplastic-anemia. Accessed Nov. 16, 2019.
4 4. Frickhofen N, Rosenfeld SJ. Immunosuppressive treatment of aplastic anemia with antithymocyte globuilin and cyclosporine. Semin Hematol. 2000; 37:56-68.
5 5. Marsh J, Schrezenmeier H, Marin P, et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anemia Working Party. Blood. 1999;93: 2191-2195.
6 6. Raghavachar A, olbe , Ho ffken K, et al. A randomized trial of standard immunosuppression versus cyclosporine and filgastrim in severe aplastic anemia [abstract]. Blood. 1997;90: 439a. Abstract 1951.
7 7. Bacigalupo A, Bruno B, Saracco P, et al. Antilymphocyte globuilin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients: European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood. 2000;95: 1931-1934.
8 8. Rosenfeld S, Follman D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003;289: 1130-1135.
9 9. Kojima S, Hibi S, Kosaka Y, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood. 2000;96: 2049-2054.
10 10. Fuhrer M, Rampf U, Baumann I, et al. Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. Blood. 2005;106: 2102-2104.
11 11. Fang JP, Xu HG, Huang SL, Chen C, Huang K. Immunosuppressive treatment of aplastic anemia in Chinese children with antithymocyte globulin and cyclosporine. Pediatr Hematol Oncol. 2006; 23: 45-50.
12 12 . Tichelli A, Socie G, Henry-Amar M, et al. Effectiveness of immunosuppressive therapy in older patients with aplastic anemia: The European Group for Blood and Marrow Transplantation Several Aplastic Anaemia Working Party. Ann Intern Med. 1999;130: 193201.
13 13. Tichelli A, Passweg J, Nissen C, et al. Repeated treatment with horse antilymphocyte globulin for severe aplastic anaemia. Br J Haematol. 1998; 100: 393-400.
14 14. Scheinberg P, Nunez O, Young NS. Retreatment with rabbit anti-thymocyte globulin and cyclosporine for patients with relapsed or refractory severe aplastic anemia. Br J Haematol. 2006;133: 622-627.
15 15. Socie G, Rosenfeld S, Frickhofen N, Gluckman E, Tichelli A. Late clonal diseases of treated aplastic anemia. Semin Hematol. 2000;37: 91-101.
16 16. Jeng MR, Naidu PE, Rieman MD, et al. Granulocyte-macrophage colony stimulating factor and immunosuppression in the treatment of pediatric acquired severe aplastic anemia. Pediatr Blood Cancer. 2005;45: 170-175
17 17. Gluckman E, Rokicka-Milewska R, Hann I, et al. Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia. Br J Haematol. 2002;119: 1075-1082.
18 18. Brodsky RA, Sensenbrenner LL, Smith BD, et al. Durable treatment-free remission after high dose cyclophosphamide therapy for previously severe aplastic anemia. Ann Intern Med. 2001;135: 477-483.
19 19. Brodsky RA, Chen A, Dorr DM, Brodsky I, Jones RJ. High dose cyclophosphamide (CY) for severe aplastic anemia (SAA): safety and long term follow-up [abstract]. Blood. 2005;106: 41a-42a. Abstract 129.
20 20. DeZern AE, et al. Haploidentical donor bone marrow transplantation for severe aplastic anemia. Hematology/Oncology Clinics of North America. 2018; doi:10.1016/j.hoc.2018.04.001.
21 21. Jeyaraman, P., Borah, P., Rajput, P., Dayal, N., Pathak, S., & Naithani, R. (2020). Daratumumab for pure red cell aplasia post ABO incompatible allogeneic hematopoietic stem cell transplant for aplastic anemia. Blood Cells, Molecules, and Diseases, 102464. doi:10.1016/j.bcmd.2020.102464.
22 22. Armand, P., & Antin, J. H. (2007). Allogeneic Stem Cell Transplantation for Aplastic Anemia. Biology of Blood and Marrow Transplantation, 13(5), 505–516. doi:10.1016/j.bbmt.2007.02.005.
В ожидании